Figure 3 | Scientific Reports

Figure 3

From: Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer

Figure 3

The overall survival of patients with breast cancer or ER-positive breast cancer. The overall survival curve of CDC25C, ERCC6L and RAD51 in breast cancer or ER-positive breast cancer. High expression of RAD51, CDC25C or ERCC6L was related to poor overall survival of patients with breast cancer or specified ER-positive breast cancer during the early follow-up period (before 15 years). The P values < 0.05 was considered to be significantly different.

Back to article page